Bryan K. Yip
BioMarin Pharmaceutical
11 Papers
25 Citations
Bryan K. Yip is an academic researcher from BioMarin Pharmaceutical. The author has contributed to research in topics: Sanfilippo syndrome & Enzyme replacement therapy. The author has an hindex of 5, co-authored 11 publications.
Chat about Author
Papers
Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB
Shih-hsin Kan,Mika Aoyagi-Scharber,Steven Q. Le,Jon Vincelette,Kazuhiro Ohmi,Sherry Bullens,Daniel J. Wendt,Terri Christianson,Pascale M.N. Tiger,Jillian R. Brown,Roger Lawrence,Bryan K. Yip,John Holtzinger,Anil Bagri,Danielle Crippen-Harmon,Kristen N. Vondrak,Zhi Chen,Chuck Hague,Josh C. Woloszynek,Diana S. Cheung,Katherine A. Webster,Evan G. Adintori,Melanie J. Lo,Wesley Wong,Paul A. Fitzpatrick,Jonathan H. LeBowitz,Brett E. Crawford,Stuart Bunting,Patricia I. Dickson,Elizabeth F. Neufeld +29 more
TL;DR: Using a mouse model of MPS IIIB, a modified NAGLU was administered by injection into the left ventricle of the brain, bypassing the blood–brain barrier, to suggest the feasibility of enzyme replacement therapy for MPSIIIB.
113
Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target.
Yedda Li,Yue Xu,Bruno A. Benitez,Murtaza S. Nagree,Joshua T. Dearborn,Xuntian Jiang,Miguel A. Guzman,Josh C. Woloszynek,Alex Giaramita,Bryan K. Yip,Joseph Elsbernd,Michael C. Babcock,Melanie Lo,Stephen C. Fowler,David F. Wozniak,Carole Vogler,Jeffrey A. Medin,Jeffrey A. Medin,Brett E. Crawford,Mark S. Sands +19 more
TL;DR: It is shown that psychosine is derived from the catabolic deacylation of galactosylceramide by the lysososomal enzyme acid ceramidase, confirming the ∼45-y-old “psychosine hypothesis” and suggesting that ACDase could be a target for substrate reduction therapy (SRT) in Krabbe patients.
79
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
TL;DR: BMN 673, a novel PARP1/2 inhibitor in clinical development with substantial tumor cytotoxicity, forms extensive hydrogen-bonding and π-stacking in the nicotinamide pocket, with its unique disubstituted scaffold extending towards the less conserved edges of the pocket.
Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.
Mika Aoyagi-Scharber,Danielle Crippen-Harmon,Roger Lawrence,Jon Vincelette,Gouri Yogalingam,Heather Prill,Bryan K. Yip,Brian Baridon,Catherine Vitelli,Amanda Lee,Olivia Gorostiza,Evan G. Adintori,Wesley C. Minto,Jeremy L. Van Vleet,Bridget Yates,Sara Rigney,Terri Christianson,Pascale M.N. Tiger,Melanie J. Lo,John Holtzinger,Paul A. Fitzpatrick,Jonathan H. LeBowitz,Sherry Bullens,Brett E. Crawford,Stuart Bunting +24 more
TL;DR: The substantial brain uptake of NAGLU attainable by this highest ICV dosage was required for nearly complete attenuation of disease-driven storage accumulations and neuropathology throughout the Naglu−/− mouse brain.
44
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
Gouri Yogalingam,Amanda R. Luu,Heather Prill,Melanie J. Lo,Bryan K. Yip,John Holtzinger,Terri Christianson,Mika Aoyagi-Scharber,Roger Lawrence,Brett E. Crawford,Jonathan H. LeBowitz +10 more
TL;DR: While receptor-independent mechanisms exist for lysosomal targeting of rhNAGLU in microglia, BMN 250, by its IGF2 tag moiety, confers increased CI-MPR-mediated lysOSomal targeting to neurons and astrocytes, two additional critical cell types of Sanfilippo B disease pathogenesis.